Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213518 | 0.81 | CA1 (0.42) | JAK2JAK1TYK2CLK4KDM4C | |
| SCHEMBL568039 | 0.81 | JAK2 (0.38) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL5078530 | 0.80 | KDM4C (0.36) | TRPV4JAK2JAK1TYK2CLK4 | |
| Hydrochloric Acid SCHEMBL28146131 | 0.80 | KDM4C (0.36) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL5078527 | 0.80 | RAD51 (0.46) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL20084360 | 0.79 | JAK2 (0.43) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL22954458 | 0.77 | JAK2 (0.43) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL29296706 | 0.75 | JAK2 (0.41) | TRPV4JAK2JAK1TYK2CLK4 | |
| SCHEMBL7016006 | 0.74 | GRM5 (0.53) | JAK2TYK2CLK4GRM5EGLN2 | |
| SCHEMBL29413268 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| CN-117304098-A | Electrolyte additive, preparation method thereof, electrolyte and lithium ion battery | 蓝固(湖州)新能源科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| US-10966980-B2 | Pyrrolo[2,3-d]pyrimidine derivatives | PFIZER INC. (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2021022178-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021022178-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2016204261-A1 | AMINOPYRAZOLE DERIVATIVES | 中外製薬株式会社 | 2016-12-22 | — | — | WO | disclosed |
| US-20160045508-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2016024185-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | PFIZER INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2958921-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | Pfizer Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| CN-105008362-A | Pyrrolo [2,3-D ] pyrimidine derivatives as janus-related kinase (JAK) inhibitors | PFIZER | 2015-10-28 | — | — | CN | disclosed |
| US-20150246048-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. | 2015-09-03 | — | — | US | disclosed |
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. | 2015-08-13 | — | — | US | disclosed |
| US-9035074-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014128591-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225408-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | TRPV4 3546/4885JAK2 3/4885JAK1 2/4885 |
| US-20220235043-A1 | SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | TRPV4 1293/4885JAK2 3/4885JAK1 1/4885 |
| US-20160045508-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | TRPV4 3589/4885JAK2 3/4885JAK1 2/4885 |
| US-10966980-B2 | Pyrrolo[2,3-d]pyrimidine derivatives | JAK3, JAK1, JAK2 | TRPV4 3589/4885JAK2 3/4885JAK1 2/4885 |
| US-20150246048-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | TRPV4 3546/4885JAK2 3/4885JAK1 2/4885 |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | TRPV4 4602/4885JAK2 1329/4885JAK1 2295/4885 |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | TRPV4 3546/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.